1
项与 SII B.1.351 ( Novavax) 相关的临床试验A Randomized, Observer-Blinded, Phase 1/2 Study With an Open-Label Group to Evaluate the Safety and Immunogenicity of SII Vaccine Constructs Based on SARS-CoV-2 Variants in Adults
This is a randomized, observer-blinded, Phase 1/2 study with an open-label group to evaluate the safety and immunogenicity of 3 novel SARS-CoV-2 variant vaccine constructs adjuvanted with Matrix-M1 adjuvant. Investigational products will include a monovalent SII SARS-CoV-2 B.1.351 (Beta) variant vaccine (SII B.1.351), a bivalent SII vaccine containing antigen for both the ancestral strain and B.1.351 (Beta) variant of SARS-CoV-2 (SII Bivalent), and a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine (SII B.1.617.2).
100 项与 SII B.1.351 ( Novavax) 相关的临床结果
100 项与 SII B.1.351 ( Novavax) 相关的转化医学
100 项与 SII B.1.351 ( Novavax) 相关的专利(医药)
100 项与 SII B.1.351 ( Novavax) 相关的药物交易